

Anti-Chromogranin A [PHE-5]

Catalog No.	Description	
AM356-5M	6 ml of Ready-to-Use Antibody for use with BioGenex Super Sensitive TM Detection Systems OR equivalent detection system	
AM356-10M	10 ml of Ready-to-Use Antibody in a barcode labeled vial for use with BioGenex Super Sensitive TM Detection Systems and i6000 TM Automated Staining Systems	
MU356-UC	1 ml of Concentrated Antibody for use with BioGenex Super Sensitive TM Detection Systems OR equivalent detection system	
MU356-5UC	0.5 ml of Concentrated Antibody for use with BioGenex Super Sensitive TM Detection Systems OR equivalent detection system	
AX356-YCD	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx® Elite/Ultra Staining System, 160 tests	
AX356-50D	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx® Elite/Ultra Staining System, 50 tests	

Clone	Species	Ig Class
PHE-5	Mouse	IgG

Intended Use

For In Vitro Diagnostic Use. This antibody is designed for the specific localization of Chromogranin A in formalin-fixed, paraffinembedded (FFPE) tissue sections. Evaluation must be performed by a qualified pathologist.

Summary and Explanation

This antibody recognizes Chromogranin A (68kD) and other related chromogranin polypeptides from human, monkey, and pig. Through immunohistochemistry, chromogranin has been demonstrated in several elements of the diffuse neuroendocrine system, including anterior pituitary, thyroid parafollicular C cells, parathyroid chief cells, pancreatic islet cells, intestinal enteroendocrine cells, and tumors derived from these cells. Chromogranin immunoreactivity was also seen in thymus, spleen, lymph nodes, fetal liver, neurons, the inner segment of rods and cones, the submandibular gland, and the central nervous system. Since it is widely distributed, the measurement of Chromogranin A has become a valuable tool in the investigation of neuroendocrine neoplasia.

Storage and Handling

Store at 2-8°C. Fresh dilutions, if required, should be prepared prior to use and are stable and steady for up to one day at room temperature (20-26°C). Diluted antibody preparations can be refrigerated or frozen for extended shelf life.

Principles of the Procedure

Antigen detection by immunohistochemistry (IHC) is a two-step process wherein the primary antibody binds to the antigen of interest and that binding is detected by a chromogen. The primary antibody may be used in IHC using manual techniques or BioGenex Automated Staining System. Positive and negative controls should always be run simultaneously with all patient specimens.

Reagents Provided

Mouse Monoclonal Antibody Chromogranin A is affinity purified and diluted in PBS, pH 7.2, containing 1% BSA and 0.09% sodium azide.

Dilution of Primary Antibody

BioGenex Ready-to-Use antibodies have been optimized for use with the recommended BioGenex Detection System and should not require further dilution.

BioGenex concentrated antibodies must be diluted in accordance with the recommended protocol when used with the recommended BioGenex Detection System.

Recommended Protocol

Refer to the following table for conditions specifically recommended for this antibody. Refer to the BioGenex website for guidance on specific staining protocols or other requirements.

Parameter	BioGenex Recommendations
Control Tissue	PANCREAS tissue as available with Biogenex FB-356M* & FG-356M*
Recommended Dilution for Concentrated Antibody	1:50-100 in HK156
Recommended Pretreatment (Manual/i6000)**	EZ-AR2 (HK522-XAK)
Recommended	EZ-AR2 Elegance
Pretreatment (Xmatrx)	(HX032-YCD)
Antibody Incubation (Manual/i6000)	30-60 Min at RT
Antibody Incubation (Xmatrx)	30-60 Min at RT
	Use BioGenex Two-Step OR
Detection System for	One-Step Super Sensitive TM
Manual, Xmatrx & i6000	Polymer-HRP IHC Detection
systems***	System/DAB; see p. 2 for more information

^{*}FB: positive control micro chamber slides, FG: positive control microscopic slides. Xmatrx requires micro chamber slides.

^{**}Pretreatment times will vary based on individual microwave power.

Category	Antibodies	Revision No.	Ι
Document No.	932-356M-EN	Release Date	18-Feb-2022

***For automation systems (Xmatrx-Elite, Xmatrx-Ultra i6000 Diagnostics), refer to the factory protocols provided with the instrument.

Detection System	Two-Step HRP Kit	One-Step HRP Kit	Link and Label Kit
Manual	QD440- XAKEN (1000 Test) QD430- XAKEN (1000 Test)	QD630-XAKE (1000 Test)	QP300-XAKE (1000 Test)
	QD420-YIKEN (500 Test) QD400-60KEN (60 Test)	QD620-XAKE (500 Test)	QP900-9LE (500 Test)
Xmatrx - Automation	QD550- YCDEN (200 Test)	QD610-YADE (200 Test)	N/A
i6000 - Automation	QD410- YAXEN (200 Test)	QD610-YAXE (200 Test)	N/A
For more information, visit www.biogenex.com.			

Precautions

This product contains sodium azide at concentrations of less than 0.1%. Sodium azide is not classified as a hazardous chemical at the product concentrations, but proper handling protocols should be observed. For more information, a Safety Data Sheet (SDS) for sodium azide is available upon request. Dispose of unused reagents according to Local, State and Federal Regulations. Wear suitable Personal Protective Equipment, do not pipette reagents by mouth, and avoid contact of reagents and specimens with skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with copious amounts of water.

Ouality Control

Refer to BioGenex detection system documents for guidance on general quality control procedures.

Troubleshooting

Refer to the troubleshooting section in the documentation for BioGenex Detection Systems (or equivalent detection systems) for remedial actions on detection system related issues, or contact BioGenex Technical Support Department at 1-800-421-4149 or support@biogenex.com or your local distributor to report

unusual staining.

Expected Results

This antibody stains cytoplasm in positive cells in formalin-fixed, paraffin embedded tissue sections. An example image of a tissue section stained with this antibody can be found on the product page on the BioGenex website. Interpretation of the staining result is solely the responsibility of the user. Experimental results should be confirmed by a medically- established diagnostic product or procedure.

Limitations of the Procedure

Improper tissue handling and processing prior to immunostaining can lead to inconsistent results. Variations in embedding and fixation or the nature of the tissue may lead to variations in results. Endogenous peroxidase activity or pseudo peroxidase activity in erythrocytes and tissue biotin may result in non-specific staining based on the detection system employed. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive with horseradish peroxidase systems . Improper counterstaining and mounting may compromise the interpretation of results.

Bibliography

- 1. Lloyd RV, et al. Pathol Annu 22:69-90, 1987.
- 2. O'Connor, DT, et al. J Clin Endocrinol Metab 57:1084, 1983.
- 3. Hendy, GN, et al. Clin Invest Med 18:47-65, 1995.
- Barbareschi M, et al. Appl Pathol 7:161-170, 1989.

2°C 8°C	Temperature Limitation	IVD	In Vitro Diagnostic Medical Device
\boxtimes	Use By Date	LOT	Batch Code
NON STERILE	Non-Sterile	i	Consult Instructions for Use
ECREP	Representative in the European Community	***	Manufacturer

© 2020, BioGenex Laboratories. All rights reserved.

Category	Antibodies	Revision No.	I
Document No.	932-356M-EN	Release Date	18-Feb-2022